Prostate Cancer

Testosterone Replacement Safe for Men With Prostate Cancer

Testosterone Replacement Safe for Men With Prostate Cancer

By

Findings emerge from a study of hypogonadal men who underwent radiation therapy, surgery, or active surveillance for prostate cancer.

Visceral Fat Predicts Prostate Cancer Treatment Outcomes

Visceral Fat Predicts Prostate Cancer Treatment Outcomes

By

Greater visceral adipose tissue volume and density are associated with a lower the risk of biochemical recurrence.

Cardiac Event Risk in PCa Patients Higher After Radiation Than Surgery

Cardiac Event Risk in PCa Patients Higher After Radiation Than Surgery

By

Radiation therapy also is associated with a greater likelihood of fractures.

Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Does not improve overall survival in metastatic castration-resistant prostate cancer.

PSA of ≥0.4 ng/mL Predicts PCa Progression

PSA of ≥0.4 ng/mL Predicts PCa Progression

Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

Midlife PSA Levels Predict Lethal Prostate Cancer

Midlife PSA Levels Predict Lethal Prostate Cancer

By

The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.

Record Numbers of Americans Are Cancer Survivors

Record Numbers of Americans Are Cancer Survivors

More effective tools are needed to support the long-term recovery of patients who survive cancer.

Many Terminal Cancer Patients Still Receive Aggressive Treatment

Many Terminal Cancer Patients Still Receive Aggressive Treatment

Three in 4 young or middle-aged patients receive aggressive therapies in the last months of life.

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.

TRUS-biopsy Inferior for Prostate Cancer Detection

TRUS-biopsy Inferior for Prostate Cancer Detection

Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.

Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.

Factors Affecting Post-Brachytherapy Urinary Incontinence Type ID'd

Factors Affecting Post-Brachytherapy Urinary Incontinence Type ID'd

By

TURP and EBRT after seed implantation are associated with development of urge urinary incontinence.

Androgen Suppression With Salvage Radiotherapy May Fight Progression

Androgen Suppression With Salvage Radiotherapy May Fight Progression

Adding short-term androgen suppression to salvage radiotherapy may benefit men with prostate cancer who have undergone radical prostatectomy.

Localized PCa Patients Misperceive Their Odds of Survival

Localized PCa Patients Misperceive Their Odds of Survival

Most patients have unrealistic survival expectations, which may compromise their ability to make informed treatment decisions.

Local Therapy Benefits Some Metastatic PCa Patients

Local Therapy Benefits Some Metastatic PCa Patients

By

Patients with a relatively low tumor risk and good general health status appear to experience the best survival.

Prostate, Bladder Cancer Linked to BPH

Prostate, Bladder Cancer Linked to BPH

By

In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.

Prognostic Cancer Screening Tools Show Promise

Prognostic Cancer Screening Tools Show Promise

High rates of screening for individuals with limited long-term life expectancy for all tools.

<i>BRCA</i> Gene Mutations May Influence Prostate Cancer Risk

<i>BRCA</i> Gene Mutations May Influence Prostate Cancer Risk

Multiple studies suggest they might.

Aminosalicylates Cut PCa Risk in Men with IBD

Aminosalicylates Cut PCa Risk in Men with IBD

By

Researchers found an adjusted 68% decreased risk of prostate cancer in men with IBD who used aminosalicylate.

PPIs Linked With Higher Rate of Post-RP Complications

PPIs Linked With Higher Rate of Post-RP Complications

By

Prostate cancer patients taking proton pump inhibitors also had pathologically higher stage disease.

Baseline PSA at Age 55-60 Predicts Prostate Cancer Risk

Baseline PSA at Age 55-60 Predicts Prostate Cancer Risk

By

The higher the baseline PSA levels, the greater the risk of being diagnosed with any or significant prostate cancer.

Salvage Radical Prostatectomy Offers Good Long-Term Outcomes

Salvage Radical Prostatectomy Offers Good Long-Term Outcomes

By

Minimally invasive surgery is associated with a lower incidence of bladder neck contracture.

Long-Term RP Outcomes Better for cT1a Prostate Cancer

Long-Term RP Outcomes Better for cT1a Prostate Cancer

By

Study documents superior recurrence- and metastasis-free survival compared with cT1b tumors.

Higher Radiation Dose Key to Better Brachytherapy Outcomes

Higher Radiation Dose Key to Better Brachytherapy Outcomes

By

A biologic effective dose less than 170 Gy2 is associated with a 2-fold increase risk dying from prostate cancer versus higher doses.

Erectile Function Recovery Better With Delayed Radiotherapy After RP

Erectile Function Recovery Better With Delayed Radiotherapy After RP

By

The chances of erectile function recovery improved when patients received radiation treatment more than 16 months after surgery.

Dutasteride Cuts Risk of Prostate Biopsy-Related UTIs

Dutasteride Cuts Risk of Prostate Biopsy-Related UTIs

By

In a study, use of the medication was associated with a significant 61% decreased risk.

Prostate Cancer Risk Not Increased With Testosterone Therapy

Prostate Cancer Risk Not Increased With Testosterone Therapy

By

In fact, some data suggest treatment may reduce prostate cancer incidence and aggressiveness.

Bladder Cancer Risk Higher Following Prostate Radiotherapy

Bladder Cancer Risk Higher Following Prostate Radiotherapy

By

The increased risk occurs more than 10 years after treatment and most pronounced in men who undergo brachytherapy.

High-Risk Prostate Cancer Linked to Poverty

High-Risk Prostate Cancer Linked to Poverty

By

In a study of African-American radical prostatectomy patients, low income predicted a higher risk of advanced stage or aggressive tumors.

Sign Up for Free e-newsletters